ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / ORMP / news
YARW (26) SION (33) ANTX (43) PEPG (35) ⌘ Pro Terminal →

Why ORMP Stock dropped -2.68% Today — RQD Quant Desk Flash

$4.00 -2.68% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $3.97

Oramed Pharmaceuticals Inc. (ORMP) carries a Roarable Rating of E (Strong Sell) with 33/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $166.4M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on ORMP Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is ORMP stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 33/100 at a spot price of $4.00 (-2.68% 1D, market cap $166.4M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 6/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, ORMP ranks #684 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does ORMP compare to YARW and SION in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ORMP carries a Roarable E (33/100 RQD), trailing P/E of N/A, gross margin of 0.7%, and ROIC of -7.8%. By comparison, YARW (Yarrow Bioscience Inc.) holds a E grade (26/100 RQD, P/E N/A, ROIC -35.0%, cap $166.8M) and SION (Sionna Therapeutics Inc.) posts a E grade (33/100 RQD, P/E N/A, ROIC -28.3%, cap $168.6M). Among the 5-stock peer group, ORMP leads on earnings multiple (N/A) while ORMP leads on capital efficiency (-7.8% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for ORMP?
▼

Per ORMP's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001176309), Oramed Pharmaceuticals Inc. generated $2.0M in revenue (-94.4% YoY), $75.3K in net income, and -$9.2M in free cash flow against $230.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $3.97 (-0.67%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (33/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-8.9% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510033
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E · Rk D
Cash (6)Whales (6)SEC (10)Macro (8)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-11.3% Base Target
$6 Bull$4 Base$3 Bear
📬 FREE ORMP RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ORMP)Realized 20D OHLCV Swing Band: ±7.6%
Deterministic 5-Pillar Attribution (33/100 Composite)
🔍 WHY ORMP SCORES 33/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (30% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9

▲ #2 Bullish Driver: Macro Regime Fit+8/20 pts (24% of score)

FRED Regime × Technicals: 57% of 52W Range • RSI-14 at 35.7 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
41
Grade D$4.14+0% Next Q
Q2 (-2Q)
38
Grade E$4.14+0.5% Next Q
Q3 (-1Q)
36
Grade E$4.16-3.8% Next Q
Current
33
Grade E$4.00-8.9% Hist 90D α
Trajectory: D (41) → E (33)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a ORMP Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While ORMP currently carries a cautious 33/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($4.52) and Max Pain ($4.20) forces dealer call-delta covering toward $5.74.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ORMP• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “ORMP Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 33%NO 67%Trade / Inspect Odds →
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →

Why ORMP Stock dropped -2.68% Today — RQD Quant Desk Flash

Oramed Pharmaceuticals Inc. (ORMP) dropped -2.68% to $4.00, trading at 57% of its 52-week range ($2.09 – $5.47). Stretched risk/reward at current multiples (-8% return on capital) under elevated 10-year interest-rate pressure.

  • ▸Technical Tape: Trading at 57% of its 52-week range ($2.09 – $5.47) with RSI-14 at 35.7 (NEUTRAL RANGE).
  • ▸Volatility Profile: Historical 20-day realized swing band of ±7.6% around $4.00 (no active unusual options sweep snapshot on file).
  • ▸Fundamental Anchor: Roarable E (Strong Sell) backed by 0.7% gross margin and $0 annual free cash flow.
Live ORMP Headlines & Catalysts
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ORMP)

  • ✓Walkthrough of ORMP's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
ORMP // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +0.50%🛡️ HOLDING TREND SUPPORT
2026-11-04O $4.11H $4.11L $4.00C $4.00VOL 97.3K
RES: $5.78SUP: $3.89SMA50: $4.52SMA200: $4.04
$5.65$4.90$4.15$3.40$2.65RES $5.78SUP $3.89$4.002026-05-052026-06-182026-08-052026-09-212026-11-04
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ORMP Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ORMP Butterfly Map → + Track ORMP →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. -94.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on ORMP today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ORMP. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for ORMP today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ORMP)

Health Care Rank #684 of 1015 ⚔️ YARW vs ORMP Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ORMP vs. YARW, SION, ANTX, PEPG)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Oramed Pharmaceuticals Inc. (ORMP) ranks #684 by composite RQD confidence (33/100, grade E) and #594 by equity capitalization ($166.4M). Within this direct 5-issuer industry benchmark cohort, ORMP leads on earnings valuation at N/A trailing P/E, while ORMP leads on capital efficiency and profitability with -7.8% ROIC and 0.7% gross margin. ANTX currently holds the highest overall quantitative score in the immediate peer group at 43/100 (D-) compared with ORMP at 33/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
ORMP ACTIVE
Oramed Pharmaceuticals Inc.
E 33/100 — 0.7% -7.8% -2.68% $166.4M Benchmark Subject
YARW
Yarrow Bioscience Inc.
E 26/100 — — -35.0% -9.90% $166.8M /yarw-vs-ormp →
SION
Sionna Therapeutics Inc.
E 33/100 — — -28.3% -3.62% $168.6M /sion-vs-ormp →
ANTX
AN2 Therapeutics Inc.
D- 43/100 — — -35.0% -3.97% $164.2M /antx-vs-ormp →
PEPG
PepGen Inc.
D- 35/100 — — -35.0% -0.42% $162.8M /pepg-vs-ormp →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001176309 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Oramed Pharmaceuticals Inc. (ORMP) reported GAAP revenue of $2.0M (-94.4% vs. FY2024 revenue of $35.8M , and +49.3% cumulative change since FY2023) , GAAP net income of $75.3K, operating cash flow of -$9.1M, and free cash flow of -$9.2M (-8.6% YoY). On the balance sheet, ORMP closed FY2025 with $230.9M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $2.0M $75.3K -$9.1M -$9.2M $230.9M —
FY2024 (FY) 2024-12-31 $35.8M -$15.9K -$8.4M -$8.4M $155.3M —
FY2023 (FY) 2023-12-31 $1.3M $5.1K -$10.3M -$10.3M — —

3. ORMP Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ORMP stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 33/100 at a spot price of $4.00 (-2.68% 1D, market cap $166.4M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 6/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, ORMP ranks #684 in composite RQD confidence.

How does ORMP compare to YARW and SION in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ORMP carries a Roarable E (33/100 RQD), trailing P/E of N/A, gross margin of 0.7%, and ROIC of -7.8%. By comparison, YARW (Yarrow Bioscience Inc.) holds a E grade (26/100 RQD, P/E N/A, ROIC -35.0%, cap $166.8M) and SION (Sionna Therapeutics Inc.) posts a E grade (33/100 RQD, P/E N/A, ROIC -28.3%, cap $168.6M). Among the 5-stock peer group, ORMP leads on earnings multiple (N/A) while ORMP leads on capital efficiency (-7.8% ROIC).

What are the biggest fundamental strengths and SEC risk factors for ORMP?

Per ORMP's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001176309), Oramed Pharmaceuticals Inc. generated $2.0M in revenue (-94.4% YoY), $75.3K in net income, and -$9.2M in free cash flow against $230.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is ORMP trading relative to its 50-day, 200-day, and 52-week technical levels?

ORMP last traded at $4.00 (-2.68% on volume of 97,267 shares), positioning the stock -11.50% below its 50-day simple moving average ($4.52) and -0.99% below its 200-day simple moving average ($4.04). Across its 52-week range of $2.09 to $5.47, ORMP sits at the 56.5% percentile with a 14-day RSI of 35.7 (NEUTRAL RANGE) and an implied next-earnings move of ±7.6% ($3.70 to $4.30).

Direct Sub-Reports: ORMP RQD Cockpit ORMP 12M Forecast ORMP Earnings & Move ORMP Dividends & DRIP ORMP Insiders & 13F ORMP Whale Options ORMP Profit Sankey ORMP News & Why
ROARABLE RATING BRIEF • RQD 33/100 (E) ✓ SEC XBRL & RQD VERIFIED

ORMP — Oramed Pharmaceuticals Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Oramed Pharmaceuticals Inc. (ORMP) earns a live Roarable RQD composite score of 33/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $4.00 (-2.68% 1D, market capitalization $166.4M).

  • Fundamental Cash Engine (6/20): Anchored by return on invested capital (ROIC) of -7.8%, gross margin of 0.7%, operating margin of -60.0%, and free cash flow yield of -5.20%.
  • Whale 13F & Options Flow (6/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (8/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 3/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

. (ORMP) is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Pharmaceutical Preparations industry. Reported revenue in the SEC financials is $2.0M for FY 2025, — for FY 2024, and $1.3M for FY 2023. Market capitalization is listed as $0.2B in the profile and $176.0M in market data.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Oramed Pharmaceuticals Inc. (ORMP) reported $2.0M in annual revenue (up from $35.8M in FY2024, -94.4% YoY) and $75.3K in GAAP net income. Over the multi-year SEC filing window from FY2023 ($1.3M revenue, $5.1K net income) through FY2025, ORMP scaled operating cash flow to -$9.1M and free cash flow to -$9.2M, backed by $230.9M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (E • RQD 33/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -5.20% and institutional whale pillar of 6/20. With Fundamental Cash Engine at 6/20 and Institutional Whale Flow at 6/20, sustained execution supports upside toward the upper end of the $2.09 – $5.47 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Upstream and downstream dependencies, sector correlations, and second-order bottlenecks cannot be assessed from the provided data beyond the sector classification (Health Care) and industry classification (Biotechnology: Pharmaceutical Preparations). A prospective investor should note that the absence of mapped links means this analysis cannot identify ripple effects from this graph.

  • Key Question #1: Can ORMP sustain or expand its -60.0% operating margin and -7.8% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $2.0M and free cash flow of -$9.2M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is ORMP's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

ORMP Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Oramed Pharmaceuticals Inc. (ORMP) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to ORMP Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

ORMP Bull vs. Bear Conversation Board — What's Your Call at $4.00?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ORMP 🐻 33% BEARISH CONVICTION
1. Pick Your Side on ORMP:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
SI SiliconVal_Bull RQD DEBATE OPENER • Growth & Tech Investor 🐂 BULLISH 🎯 Target: $5.38 (+30.9%)
📌 Pinned Debate

Reported cash of $45.9M and a mid-range Altman Z-Score of 2.5 provide a balance-sheet buffer against ongoing free-cash-flow losses of $

Don't sleep on ORMP's setup in Health Care. Reported cash of $45.9M and a mid-range Altman Z-Score of 2.5 provide a balance-sheet buffer against ongoing free-cash-flow losses of -$9.2M.. Beta of 1.0 means it moves fast when momentum turns, and the 5-pillar RQD gauge (33/100) backs up the fundamental quality.

SectorRotator 🐂 BULL

@RiskArb_Desk Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Biotechnology: Pharmaceutical Preparations. If gross margin (0.7%) holds, EPS grows into the multiple faster than bears think.

RI RiskArb_Desk RQD DEBATE OPENER • Hedged Event Driven 🐻 BEARISH 🎯 Target: $3.37 (-18.0%)
Spot @ $4.11

Operating income of -$15.1M, negative ROIC of -7.8%, and an insider-conviction pillar score of 3 / 20 indicate weak cash generation and

Fading this rally in ORMP at $4.11. Operating income of -$15.1M, negative ROIC of -7.8%, and an insider-conviction pillar score of 3 / 20 indicate weak cash generation and limited insider support.. With a beta of 1.0 and the stock sitting at $4.11 (52-wk range $2.09–$5.47), the easy multiple expansion is already priced in.

LIVE TAPE